- Home
- NRXS vs MTVA Comparison
NRXS vs MTVA Comparison
Compare NRXS & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- MTVA
- Stock Information
- Founded
- NRXS 2011
- MTVA 2014
- Country
- NRXS United States
- MTVA United States
- Employees
- NRXS N/A
- MTVA N/A
- Industry
- NRXS
- MTVA
- Sector
- NRXS
- MTVA
- Exchange
- NRXS Nasdaq
- MTVA NYSE
- Market Cap
- NRXS 12.5M
- MTVA 13.6M
- IPO Year
- NRXS 2023
- MTVA N/A
- Fundamental
- Price
- NRXS $2.40
- MTVA $0.83
- Analyst Decision
- NRXS
- MTVA Strong Buy
- Analyst Count
- NRXS 0
- MTVA 1
- Target Price
- NRXS N/A
- MTVA $12.00
- AVG Volume (30 Days)
- NRXS 36.9K
- MTVA 1.4M
- Earning Date
- NRXS 05-21-2025
- MTVA 05-08-2025
- Dividend Yield
- NRXS N/A
- MTVA N/A
- EPS Growth
- NRXS N/A
- MTVA N/A
- EPS
- NRXS N/A
- MTVA N/A
- Revenue
- NRXS $2,685,925.00
- MTVA N/A
- Revenue This Year
- NRXS $138,883.78
- MTVA N/A
- Revenue Next Year
- NRXS $118.59
- MTVA N/A
- P/E Ratio
- NRXS N/A
- MTVA N/A
- Revenue Growth
- NRXS 9.18
- MTVA N/A
- 52 Week Low
- NRXS $1.33
- MTVA $0.71
- 52 Week High
- NRXS $3.78
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- NRXS 65.87
- MTVA N/A
- Support Level
- NRXS $1.33
- MTVA N/A
- Resistance Level
- NRXS $2.09
- MTVA N/A
- Average True Range (ATR)
- NRXS 0.36
- MTVA 0.00
- MACD
- NRXS 0.06
- MTVA 0.00
- Stochastic Oscillator
- NRXS 90.95
- MTVA 0.00
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.